{"transactions":[{"id":671355,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47000,"price":41.21,"value":1936870.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":43.79,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671354,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"price":48.14,"value":3129100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":36.86,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671353,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":87000,"price":41.49,"value":3609630.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":43.51,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":87000},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671352,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":110000,"price":65.36,"value":7189600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":19.64,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671351,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":77000,"price":64.98,"value":5003460.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":20.02,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":77000},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671350,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"price":61.81,"value":927150.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":23.19,"expiration_date":"2031-09-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671349,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85000,"price":69.71,"value":5925350.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":15.29,"expiration_date":"2031-02-26","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671348,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"price":62.39,"value":3743400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":22.61,"expiration_date":"2030-02-24","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671347,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":56250,"price":59.81,"value":3364312.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":25.19,"expiration_date":"2029-03-08","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671346,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":74540,"price":75.72,"value":5644168.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":9.28,"expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":74540},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671345,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90514,"price":83.09,"value":7520808.26,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":90514},"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671344,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":79650,"price":85,"value":6770250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a \"Company RSU\"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":671343,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-01T20:54:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":58286,"price":85,"value":4954310.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":79650,"source":{"system":"sec-edgar","filing":"0001628280-26-059884","document":"wk-form4_1788296075.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026059884/wk-form4_1788296075.xml","form_type":"4"}},{"id":835214,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-18T21:11:17.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":4241,"price":37.77,"value":160182.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":137101,"source":{"system":"sec-edgar","filing":"0001628280-26-019498","document":"wk-form4_1773868275.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026019498/wk-form4_1773868275.xml","form_type":"4"}},{"id":835213,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-18T21:11:17.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":6371,"price":37.11,"value":236427.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":141342,"source":{"system":"sec-edgar","filing":"0001628280-26-019498","document":"wk-form4_1773868275.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026019498/wk-form4_1773868275.xml","form_type":"4"}},{"id":882222,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-25T21:34:10.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026."}],"balance_after":47000,"derivative":{"exercise_price":43.79,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001628280-26-011718","document":"wk-form4_1772055248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026011718/wk-form4_1772055248.xml","form_type":"4"}},{"id":882221,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-25T21:34:10.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027."}],"balance_after":147713,"source":{"system":"sec-edgar","filing":"0001628280-26-011718","document":"wk-form4_1772055248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828026011718/wk-form4_1772055248.xml","form_type":"4"}},{"id":958333,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-29T21:36:41.000Z","date":"2025-12-26","kind":"exercise","planned":false,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested in 48 equal monthly installments beginning on April 16, 2018."}],"balance_after":90514,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001628280-25-059009","document":"wk-form4_1767044199.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828025059009/wk-form4_1767044199.xml","form_type":"4"}},{"id":958332,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-29T21:36:41.000Z","date":"2025-12-26","kind":"exercise","planned":false,"acquired":true,"shares":18000,"price":1.91,"value":34380.0,"ownership":{"direct":true},"balance_after":117713,"source":{"system":"sec-edgar","filing":"0001628280-25-059009","document":"wk-form4_1767044199.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000162828025059009/wk-form4_1767044199.xml","form_type":"4"}},{"id":1109992,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:48:09.000Z","date":"2025-06-12","kind":"exercise","planned":true,"acquired":false,"shares":16645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested in 48 equal monthly installments beginning on June 25, 2018."}],"balance_after":58198,"derivative":{"exercise_price":9.28,"expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":16645},"source":{"system":"sec-edgar","filing":"0000950170-25-086804","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017025086804/ownership.xml","form_type":"4"}},{"id":1109991,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:48:09.000Z","date":"2025-06-12","kind":"exercise","planned":true,"acquired":false,"shares":71525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested in 48 equal monthly installments beginning on April 16, 2018."}],"balance_after":108514,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":71525},"source":{"system":"sec-edgar","filing":"0000950170-25-086804","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017025086804/ownership.xml","form_type":"4"}},{"id":1109990,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-16T20:48:09.000Z","date":"2025-06-12","kind":"sale","planned":true,"acquired":false,"shares":97483,"price":32.23,"value":3141877.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $32.23 per share. The range of sales prices on the transaction date was $31.67 to $32.65 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":99713,"source":{"system":"sec-edgar","filing":"0000950170-25-086804","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017025086804/ownership.xml","form_type":"4"}},{"id":1109989,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-16T20:48:09.000Z","date":"2025-06-12","kind":"exercise","planned":true,"acquired":true,"shares":16645,"price":9.28,"value":154465.6,"ownership":{"direct":true},"balance_after":197196,"source":{"system":"sec-edgar","filing":"0000950170-25-086804","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017025086804/ownership.xml","form_type":"4"}},{"id":1109988,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-16T20:48:09.000Z","date":"2025-06-12","kind":"exercise","planned":true,"acquired":true,"shares":71525,"price":1.91,"value":136612.75,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 438 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":180551,"source":{"system":"sec-edgar","filing":"0000950170-25-086804","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017025086804/ownership.xml","form_type":"4"}},{"id":1194799,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-21T22:32:29.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":291,"price":34.83,"value":10135.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.83 per share. The range of sales prices on the transaction date was $34.78 to $35.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":108588,"source":{"system":"sec-edgar","filing":"0000950170-25-043402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017025043402/ownership.xml","form_type":"4"}},{"id":1194798,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-21T22:32:29.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":5479,"price":34.17,"value":187217.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.17 per share. The range of sales prices on the transaction date was $33.78 to $34.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":108879,"source":{"system":"sec-edgar","filing":"0000950170-25-043402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017025043402/ownership.xml","form_type":"4"}},{"id":1249918,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-24T21:30:04.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025."}],"balance_after":65000,"derivative":{"exercise_price":36.86,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000950170-25-025664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017025025664/ownership.xml","form_type":"4"}},{"id":1249917,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-24T21:30:04.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2026."}],"balance_after":114358,"source":{"system":"sec-edgar","filing":"0000950170-25-025664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017025025664/ownership.xml","form_type":"4"}},{"id":1291959,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-29T21:30:05.000Z","date":"2024-11-20","kind":"other","planned":false,"acquired":true,"shares":451,"price":14.98,"value":6755.98,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),"}],"balance_after":71358,"source":{"system":"sec-edgar","filing":"0000950170-25-010531","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017025010531/ownership.xml","form_type":"5"}},{"id":1326927,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-18T21:30:03.000Z","date":"2024-12-16","kind":"exercise","planned":false,"acquired":false,"shares":2331,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":180039,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":2331},"source":{"system":"sec-edgar","filing":"0000950170-24-137923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024137923/ownership.xml","form_type":"4"}},{"id":1326926,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-18T21:30:03.000Z","date":"2024-12-16","kind":"exercise","planned":false,"acquired":true,"shares":2331,"price":1.91,"value":4452.21,"ownership":{"direct":true},"balance_after":71358,"source":{"system":"sec-edgar","filing":"0000950170-24-137923","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024137923/ownership.xml","form_type":"4"}},{"id":1408821,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-09-12T20:30:03.000Z","date":"2024-09-10","kind":"sale","planned":true,"acquired":false,"shares":1035,"price":51.5,"value":53302.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $51.50 per share. The range of sales prices on the transaction date was $51.10 to $51.97 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":68576,"source":{"system":"sec-edgar","filing":"0000950170-24-105952","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024105952/ownership.xml","form_type":"4"}},{"id":1421018,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-28T20:31:24.000Z","date":"2024-08-26","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":53.19,"value":159570.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":69611,"source":{"system":"sec-edgar","filing":"0000950170-24-101434","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024101434/ownership.xml","form_type":"4"}},{"id":1433885,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-14T20:30:04.000Z","date":"2024-08-12","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":47.68,"value":143040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $47.68 per share. The range of sales prices on the transaction date was $47.60 to $47.80 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":72611,"source":{"system":"sec-edgar","filing":"0000950170-24-097085","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024097085/ownership.xml","form_type":"4"}},{"id":1448161,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-07-26T20:38:09.000Z","date":"2024-07-25","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":53.43,"value":160290.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $53.43 per share. The range of sales prices on the transaction date was $53.41 to $53.45 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":75611,"source":{"system":"sec-edgar","filing":"0000950170-24-086935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024086935/ownership.xml","form_type":"4"}},{"id":1455424,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-07-12T20:30:04.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":48.55,"value":145650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $48.55 per share. The range of sales prices on the transaction date was $48.63 to $48.46 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 968 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":78611,"source":{"system":"sec-edgar","filing":"0000950170-24-083221","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024083221/ownership.xml","form_type":"4"}},{"id":1468828,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-06-26T20:32:58.000Z","date":"2024-06-25","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":45.37,"value":136110.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $45.37 per share. The range of sales prices on the transaction date was $45.16 to $46.06 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":80643,"source":{"system":"sec-edgar","filing":"0000950170-24-077905","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024077905/ownership.xml","form_type":"4"}},{"id":1483739,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-06-11T20:35:56.000Z","date":"2024-06-10","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":43.86,"value":131580.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":83643,"source":{"system":"sec-edgar","filing":"0000950170-24-071971","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024071971/ownership.xml","form_type":"4"}},{"id":1498063,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-30T20:28:48.000Z","date":"2024-05-28","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":47.49,"value":142470.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $47.49 per share. The range of sales prices on the transaction date was $47.24 to $48.01 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":86643,"source":{"system":"sec-edgar","filing":"0000950170-24-066657","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024066657/ownership.xml","form_type":"4"}},{"id":1517745,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-14T22:29:59.000Z","date":"2024-05-10","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":49.43,"value":148290.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":89643,"source":{"system":"sec-edgar","filing":"0000950170-24-059865","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000095017024059865/ownership.xml","form_type":"4"}},{"id":1566223,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-20T22:33:23.000Z","date":"2024-03-18","kind":"tax_withholding","planned":true,"acquired":false,"shares":3655,"price":38.14,"value":139401.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022 and March 1, 2023.  The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":92643,"source":{"system":"sec-edgar","filing":"0001209191-24-005010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919124005010/doc4.xml","form_type":"4"}},{"id":1592119,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-07T00:57:15.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":87000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024."}],"balance_after":87000,"derivative":{"exercise_price":43.51,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":87000},"source":{"system":"sec-edgar","filing":"0001209191-24-004604","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919124004604/doc4.xml","form_type":"4"}},{"id":1592118,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-07T00:57:15.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025."}],"balance_after":96298,"source":{"system":"sec-edgar","filing":"0001209191-24-004604","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919124004604/doc4.xml","form_type":"4"}},{"id":1669803,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-26T22:50:17.000Z","date":"2024-01-25","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":37.26,"value":111780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $37.26 per share. The range of sales prices on the transaction date was $37.21 to $37.34 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":73298,"source":{"system":"sec-edgar","filing":"0001209191-24-002314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919124002314/doc4.xml","form_type":"4"}},{"id":1680160,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-12T21:12:25.000Z","date":"2024-01-10","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":37.65,"value":112950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan."}],"balance_after":76298,"source":{"system":"sec-edgar","filing":"0001209191-24-001510","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919124001510/doc4.xml","form_type":"4"}},{"id":1699601,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-27T22:20:25.000Z","date":"2023-12-26","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":35.89,"value":107670.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.89 per share. The range of sales prices on the transaction date was $35.77 to $36.02 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":79298,"source":{"system":"sec-edgar","filing":"0001209191-23-059809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919123059809/doc4.xml","form_type":"4"}},{"id":1712789,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-13T21:44:53.000Z","date":"2023-12-11","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":32.87,"value":98610.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $32.87 per share. The range of sales prices on the transaction date was $32.84 to $33.50 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":82298,"source":{"system":"sec-edgar","filing":"0001209191-23-058503","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919123058503/doc4.xml","form_type":"4"}},{"id":1727833,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-11-29T21:31:29.000Z","date":"2023-11-27","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":31.84,"value":95520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $31.84 per share. The range of sales prices on the transaction date was $31.41 to $31.94 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,419 shares acquired under the Issuer's Employee Stock Purchase."}],"balance_after":85298,"source":{"system":"sec-edgar","filing":"0001209191-23-056904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919123056904/doc4.xml","form_type":"4"}},{"id":1947603,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-17T21:07:31.000Z","date":"2023-03-16","kind":"tax_withholding","acquired":false,"shares":1410,"price":17.12,"value":24139.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022.  The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":86879,"source":{"system":"sec-edgar","filing":"0001209191-23-019760","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919123019760/doc4.xml","form_type":"4"}},{"id":1974781,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T21:38:55.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023."}],"balance_after":110000,"derivative":{"exercise_price":19.64,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-23-015578","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919123015578/doc4.xml","form_type":"4"}},{"id":1974780,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:38:55.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":23600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024."}],"balance_after":88289,"source":{"system":"sec-edgar","filing":"0001209191-23-015578","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919123015578/doc4.xml","form_type":"4"}},{"id":2033463,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-03T21:30:56.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":3126,"price":19.59,"value":61238.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":64689,"source":{"system":"sec-edgar","filing":"0001209191-23-006872","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919123006872/doc4.xml","form_type":"4"}},{"id":2043870,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-27T21:26:41.000Z","date":"2023-01-25","kind":"sale","acquired":false,"shares":8336,"price":21.07,"value":175639.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $21.07 per share. The range of sales prices on the transaction date was $21.00 to $21.08 per share.  Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":67815,"source":{"system":"sec-edgar","filing":"0001209191-23-005252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919123005252/doc4.xml","form_type":"4"}},{"id":2051030,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-19T21:28:37.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":3126,"price":18,"value":56268.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":76151,"source":{"system":"sec-edgar","filing":"0001209191-23-004021","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919123004021/doc4.xml","form_type":"4"}},{"id":2063166,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-05T21:23:09.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":3126,"price":18.35,"value":57362.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":79277,"source":{"system":"sec-edgar","filing":"0001209191-23-001846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919123001846/doc4.xml","form_type":"4"}},{"id":2082068,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-19T22:11:22.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":3126,"price":16,"value":50016.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 561 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2022 by the Reporting Person."}],"balance_after":82403,"source":{"system":"sec-edgar","filing":"0001209191-22-061986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122061986/doc4.xml","form_type":"4"}},{"id":2096503,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-05T22:28:56.000Z","date":"2022-12-01","kind":"sale","acquired":false,"shares":3126,"price":17.84,"value":55767.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":84968,"source":{"system":"sec-edgar","filing":"0001209191-22-059779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122059779/doc4.xml","form_type":"4"}},{"id":2112626,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-11-17T21:46:16.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":3126,"price":18.72,"value":58518.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":88094,"source":{"system":"sec-edgar","filing":"0001209191-22-057585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122057585/doc4.xml","form_type":"4"}},{"id":2125924,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-11-03T20:35:02.000Z","date":"2022-11-01","kind":"sale","acquired":false,"shares":3126,"price":18.52,"value":57893.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":91220,"source":{"system":"sec-edgar","filing":"0001209191-22-055522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122055522/doc4.xml","form_type":"4"}},{"id":2134892,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-10-19T21:34:02.000Z","date":"2022-10-17","kind":"sale","acquired":false,"shares":3126,"price":17.73,"value":55423.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":94346,"source":{"system":"sec-edgar","filing":"0001209191-22-054104","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122054104/doc4.xml","form_type":"4"}},{"id":2142407,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-10-05T20:40:15.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":3126,"price":19.64,"value":61394.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":97472,"source":{"system":"sec-edgar","filing":"0001209191-22-052769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122052769/doc4.xml","form_type":"4"}},{"id":2156054,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-09-19T20:40:37.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":4168,"price":21.01,"value":87569.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":100598,"source":{"system":"sec-edgar","filing":"0001209191-22-050529","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122050529/doc4.xml","form_type":"4"}},{"id":2162439,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-09-09T20:20:15.000Z","date":"2022-09-07","kind":"sale","acquired":false,"shares":1042,"price":21.0017,"value":21883.7714,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":104766,"source":{"system":"sec-edgar","filing":"0001209191-22-049311","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122049311/doc4.xml","form_type":"4"}},{"id":2165989,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-09-06T20:20:16.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":3126,"price":18.59,"value":58112.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":105808,"source":{"system":"sec-edgar","filing":"0001209191-22-048734","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122048734/doc4.xml","form_type":"4"}},{"id":2165988,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-09-06T20:20:16.000Z","date":"2022-05-20","kind":"other","acquired":true,"shares":1336,"price":11.02,"value":14722.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c)."}],"balance_after":108934,"source":{"system":"sec-edgar","filing":"0001209191-22-048734","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122048734/doc4.xml","form_type":"4"}},{"id":2282536,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-05-04T21:01:17.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":3247,"price":20.096,"value":65251.712,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $20.096 per share. The range of sales prices on the transaction date was $20.06 to $21.00 per share.  Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":107598,"source":{"system":"sec-edgar","filing":"0001209191-22-027145","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122027145/doc4.xml","form_type":"4"}},{"id":2292889,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-21T21:00:16.000Z","date":"2022-04-18","kind":"sale","acquired":false,"shares":5664,"price":25.81,"value":146187.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":110845,"source":{"system":"sec-edgar","filing":"0001209191-22-025190","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122025190/doc4.xml","form_type":"4"}},{"id":2302738,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-06T23:08:05.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":9000,"price":23.9735,"value":215761.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $23.9735 per share. The range of sales prices on the transaction date was $23.9515 to $24.0027 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":116509,"source":{"system":"sec-edgar","filing":"0001209191-22-023556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122023556/doc4.xml","form_type":"4"}},{"id":2311519,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-01T21:39:05.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":4164,"price":21.8,"value":90775.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":125509,"source":{"system":"sec-edgar","filing":"0001209191-22-022036","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122022036/doc4.xml","form_type":"4"}},{"id":2311518,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-01T21:39:05.000Z","date":"2022-03-31","kind":"sale","acquired":false,"shares":4164,"price":21.0614,"value":87699.6696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $21.0614 per share. The range of sales prices on the transaction date was $21.0201 to $21.0774 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":129673,"source":{"system":"sec-edgar","filing":"0001209191-22-022036","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122022036/doc4.xml","form_type":"4"}},{"id":2328171,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-17T20:33:06.000Z","date":"2022-03-15","kind":"sale","acquired":false,"shares":3123,"price":18.94,"value":59149.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":133837,"source":{"system":"sec-edgar","filing":"0001209191-22-019595","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122019595/doc4.xml","form_type":"4"}},{"id":2361484,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-03T02:00:31.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":77000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022."}],"balance_after":77000,"derivative":{"exercise_price":20.02,"expiration_date":"2032-02-27","underlying":"Common Stock","underlying_shares":77000},"source":{"system":"sec-edgar","filing":"0001209191-22-015130","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122015130/doc4.xml","form_type":"4"}},{"id":2361483,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-03T02:00:31.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":3123,"price":19.73,"value":61616.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":136960,"source":{"system":"sec-edgar","filing":"0001209191-22-015130","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122015130/doc4.xml","form_type":"4"}},{"id":2361482,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-03T02:00:31.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023."}],"balance_after":140083,"source":{"system":"sec-edgar","filing":"0001209191-22-015130","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122015130/doc4.xml","form_type":"4"}},{"id":2388919,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2022-02-17T21:34:58.000Z","date":"2022-02-15","kind":"sale","acquired":false,"shares":3123,"price":18.64,"value":58212.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":123583,"source":{"system":"sec-edgar","filing":"0001209191-22-010784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122010784/doc4.xml","form_type":"4"}},{"id":2414428,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2022-02-03T21:30:39.000Z","date":"2022-02-01","kind":"sale","acquired":false,"shares":3123,"price":18.79,"value":58681.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 954 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2021 by the Reporting Person."}],"balance_after":126706,"source":{"system":"sec-edgar","filing":"0001209191-22-006797","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122006797/doc4.xml","form_type":"4"}},{"id":2430899,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2022-01-20T21:47:53.000Z","date":"2022-01-18","kind":"sale","acquired":false,"shares":4168,"price":23.29,"value":97072.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":128875,"source":{"system":"sec-edgar","filing":"0001209191-22-004051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122004051/doc4.xml","form_type":"4"}},{"id":2441844,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2022-01-06T21:37:22.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":7168,"price":28.02,"value":200847.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":133043,"source":{"system":"sec-edgar","filing":"0001209191-22-002197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919122002197/doc4.xml","form_type":"4"}},{"id":2456307,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2021-12-31T00:19:38.000Z","date":"2021-12-28","kind":"sale","acquired":false,"shares":3000,"price":27.9506,"value":83851.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.9506 per share. The range of sales prices on the transaction date was $27.950 to $27.952 per share.  Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":140211,"source":{"system":"sec-edgar","filing":"0001209191-21-071646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919121071646/doc4.xml","form_type":"4"}},{"id":2466765,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2021-12-17T21:28:44.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":5668,"price":24.14,"value":136825.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":143211,"source":{"system":"sec-edgar","filing":"0001209191-21-070272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919121070272/doc4.xml","form_type":"4"}},{"id":2486461,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2021-12-03T21:36:33.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":5668,"price":27.38,"value":155189.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":148879,"source":{"system":"sec-edgar","filing":"0001209191-21-067840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919121067840/doc4.xml","form_type":"4"}},{"id":2508007,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-11-17T22:01:06.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":1500,"price":27.97,"value":41955.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":154547,"source":{"system":"sec-edgar","filing":"0001209191-21-065149","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919121065149/doc4.xml","form_type":"4"}},{"id":2508006,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2021-11-17T22:01:06.000Z","date":"2021-11-15","kind":"sale","acquired":false,"shares":5668,"price":26.75,"value":151619.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":156047,"source":{"system":"sec-edgar","filing":"0001209191-21-065149","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919121065149/doc4.xml","form_type":"4"}},{"id":2519968,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2021-11-09T22:44:59.000Z","date":"2021-11-08","kind":"sale","acquired":false,"shares":3900,"price":28.422,"value":110845.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $28.422 per share. The range of sales prices on the transaction date was $28.340 to $28.500 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":161715,"source":{"system":"sec-edgar","filing":"0001209191-21-063679","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919121063679/doc4.xml","form_type":"4"}},{"id":2519967,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2021-11-09T22:44:59.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":12600,"price":27.952,"value":352195.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.952 per share. The range of sales prices on the transaction date was $27.950 to $27.959 per share.  Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":165615,"source":{"system":"sec-edgar","filing":"0001209191-21-063679","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919121063679/doc4.xml","form_type":"4"}},{"id":2526793,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2021-11-03T20:57:15.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":5668,"price":24.79,"value":140509.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":178215,"source":{"system":"sec-edgar","filing":"0001209191-21-062731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919121062731/doc4.xml","form_type":"4"}},{"id":2532928,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2021-10-28T21:00:25.000Z","date":"2021-10-27","kind":"sale","acquired":false,"shares":3000,"price":23.997,"value":71991.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $23.997 per share. The range of sales prices on the transaction date was $23.970 to $24.003 per share.  Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":183883,"source":{"system":"sec-edgar","filing":"0001209191-21-061915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919121061915/doc4.xml","form_type":"4"}},{"id":2535706,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":18010,"kind":"person","name":"Betz Stephen F.","position":1,"cik":"0001886575","reported_name":"Betz Stephen F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2021-10-25T20:28:18.000Z","date":"2021-10-21","kind":"sale","acquired":false,"shares":1042,"price":21.0975,"value":21983.595,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":186883,"source":{"system":"sec-edgar","filing":"0001209191-21-061496","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886575/000120919121061496/doc4.xml","form_type":"4"}}]}